Dawn Bordeaux, one of the founders of Gentris, was promoted to a new position on Wednesday as the company prepares to enter the diagnostics market.
Bordeaux will serve as vice president of regulatory affairs and quality assurance. She had served as executive director of quality assurance.
Gentris is preparing to seek regulatory approval for its first diagnostic product.
“Ms. Bordeaux has successfully managed the attainment of several important corporate milestones, and she is uniquely qualified to manage her new portfolio of responsibilities,” said Michael Murphy, president and CEO of Gentris.
Gentris develops products to predict drug efficacy and prevent adverse reactions. Its diagnostic products are intended to provide physicians and patients specific pharmacogenomics testing for individualized medicine.